Clinical Trial Update: Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating celecoxib with or without eflornithine for prevention of colorectal cancer in patients with familial adenomatous polyposis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Familial Adenomatous Polyposis

Drugs mentioned

• Celecoxib (Celecoxib)
• Eflornithine (eflornithine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Colorectal Cancer, Familial Adenomatous Polyposis | Phase 2 | Status: COMPLETED | Results posted: 2015-02-04